Podcasts about nccn guidelines

Listen in as Jonathan A. Bernstein, MD, and Ryan Haumschild, PharmD, MS, MBA, CPEL, discuss how to manage the multidisciplinary care of patients with systemic mastocytosis (SM) from both the allergy/immunology and pharmacy perspective, including:Strategies to better identify patients presenting with features of SM to facilitate timely diagnosisCurrent guideline-recommended treatment approachesEmerging data on new targeted agents for SMPharmacist-led strategies to help patients achieve better outcomes (e.g., specialist referral, polypharmacy counseling, and anaphylaxis education)PresentersJonathan A. Bernstein, MDProfessor of MedicineDivision of Rheumatology, Allergy and ImmunologyDepartment of Internal MedicineUniversity of Cincinnati College of MedicinePartner Advanced Allergy Services, LLCPartner Bernstein Clinical Research Center, LLCCincinnati, OhioRyan Haumschild, PharmD, MS, MBA, CPELVice President of Pharmacy, AmbulatoryEmory HealthcareWinship Cancer InstituteAtlanta, GeorgiaFull link to program page:https://bit.ly/3HcA8z2

Learn how your treatment plan is decided and terms you may seeWe continue our series to help you understand cancer and its treatment. This week we focus on surgery, the oldest form of cancer treatment. Learn about surgery timing, types of cancer surgery, and how NCCN evidence-based guidelines provide a standard treatment path no matter where you are.In this Episode:02:58 - Wisconsin-Cheese, UFOs, and Booyah Stew04:52 - Anna Quindlen: Get a Life Where You Are Generous"08:06 - Medical Specialists Involved in Cancer Care08:52 - Treatment Decisions, Tumor Board and NCCN Guidelines12:03 - Adjuvant and Neoadjuvant Therapy13:13 - Surgery Timing, Reasons and Types18:00 - Discussion - NCCN and Role of Research24:34 - Reeves Keyworth:“On Loved Ones Telling the Dying to ‘Let Go”23:54 - OutroSurgery, radiation therapy, and chemotherapy alone or in combination are the most-common methods used to treat cancer. Specific treatment varies depending on the kind of cancer, the extent of the disease, its rate of progression, and the condition of the person. Surgery alone may not result in a cure and often chemotherapy and/or radiation are needed after surgery. Learn all about surgery and the guidelines your doctor will be following for your treatment.Support the showGet show notes and resources at our website: every1dies.org. Facebook | Instagram | YouTube | mail@every1dies.org

In this episode, listen to Virginia Kaklamani, MD, DSc; Erica L. Mayer, MD, MPH; and Laura M. Spring, MD, share their clinical insights and takeaways from a live symposium, including from key abstracts presented at the 2024 San Antonio Breast Cancer Symposium:Estrogen Receptor Mutations in Patients With HR-Positive/HER2-Negative Advanced Breast CancerCurrent Guideline Recommendations for When to Pursue ESR1 Mutation Testing Mutations in Patients With HR-Positive/HER2-Negative Advanced Breast CancerChoice and Sequencing of Next Line of Systemic Therapy for ESR1-Mutated Advanced Breast Cancer Based on Tumor Molecular AlterationsOverview of Class-Related and Unique Adverse Events With Approved and Emerging Oral SERDSExpert Recommendations for the Management of Oral SERDs-Related Adverse EventsProgram faculty:Virginia Kaklamani, MD, DScProfessor of MedicineRuth McLean Bowman Bowers Chair in Breast Cancer Research and TreatmentA.B. Alexander Distinguished Chair in Oncology LeaderBreast Oncology ProgramUT Health San AntonioMD Anderson Cancer CenterSan Antonio, TexasErica L. Mayer, MD, MPHDirector of Breast Cancer Clinical ResearchDana-Farber Cancer InstituteAssociate Professor in MedicineHarvard Medical SchoolBoston, MassachusettsLaura M. Spring, MDBreast Medical OncologistMass General Hospital Cancer CenterHarvard Medical SchoolBoston, Massachusetts Resources:To download the slides associated with this podcast discussion, please visit the program page.

Eric Jonasch, Co-Chair of the NCCN RCC Guidelines, gives insight into the process of guideline modification and discusses updates in adjuvant, front-line and refractory RCC

In this podcast episode, Farrukh Awan, MD, Jeremy S. Abramson, MD, MMSc, and Shuo Ma, MD, PhD, discuss real-world patient cases and how to align current clinical practice with the NCCN guidelines for CLL/SLL, including:Prognostic variables when deciding between regimensRole of MRD in CLLResults from the phase II CAPTIVATE trialChoosing among the available covalent BTK inhibitorsPreferred partner anti-CD20 antibody in CLL/SLLRole of the noncovalent BTK inhibitor, pirtobrutinib, in CLL/SLLUse of CAR T-cell therapy in CLL/SLLPresenters:Farrukh Awan, MDProfessor of Internal MedicineDirector of Lymphoid Malignancies ProgramHarold C. Simmons Comprehensive Cancer CenterUniversity of Texas Southwestern Medical CenterDallas, TexasJeremy S. Abramson, MD, MMScDirector, Center for LymphomaMassachusetts General HospitalAssociate Professor of MedicineHarvard Medical SchoolBoston, MassachusettsShuo Ma, MD, PhDProfessor of MedicineDivision of Hematology-OncologyDepartment of MedicineRobert H. Lurie Comprehensive Cancer CenterNorthwestern University Feinberg School of MedicineChicago, IllinoisContent based on an online CME program supported by educational grants from BeiGene; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; and Lilly, and an independent medical education grant from AbbVie.Link to full program:https://bit.ly/3LzA2As

In this 4th year medical student (MS4) series, we chat about the field of Radiation Oncology. Our guest, Dylan Ross, shares advice on how to set yourself up for success regarding matching into this competitive specialty and shares tips to help you stand out both on paper and in person. Dylan Ross, MD, attended the University of Minnesota for his undergraduate education where he met his now fiancée, Lindsey Greenlund, who is also a recent medical school graduate. While at Stritch, Dylan got involved with medical education and research with the radiation oncology department which were influential in his specialty decision. After a successful couple's match, Dylan is heading to Johns Hopkins for his radiation oncology residency following a transitional year at HCA Riverside Community Hospital. To connect with Dylan, email him at dross8@luc.edu  Resources mentioned in the podcast: NCCN Guidelines and Essentials of Clinical Radiation Oncology (The Red Book) Episode produced by: Rasa Valiauga Episode recording date: 3/27/24 www.medicuspodcast.com | medicuspodcast@gmail.com | Donate: http://bit.ly/MedicusDonate --- Send in a voice message: https://podcasters.spotify.com/pod/show/medicus/message

In this episode, Danielle M. Brander, MD; Deborah Stephens, DO; and Brian Hill, MD, PhD, discuss key aspects of the NCCN CLL guidelines and share strategies for applying these recommendations in your clinical practice to optimize treatment and outcomes. The greater discussion addresses:Optimal selection of therapy for treatment-naive CLL, including second-generation covalent BTK inhibitorsConsiderations in therapy selection for previously treated CLLNovel strategies for treating CLL Presenters:Danielle M. Brander, MDAssistant Professor of MedicineDivision of Hematologic Malignancies and Cellular TherapyDuke Cancer InstituteDurham, North CarolinaBrian Hill, MD, PhDDirector, Lymphoid Malignancies ProgramStaff Physician, Department of Hematology and Medical OncologyTaussig Cancer InstituteCleveland ClinicCleveland, OhioDeborah Stephens, DOAssociate ProfessorDirector of the CLL ProgramLineberger Comprehensive Cancer CenterUniversity of North CarolinaChapel Hill, North CarolinaContent based on a live and online CME program supported by educational grants from AstraZeneca; BeiGene, Ltd.; and Lilly.Link to full program including downloadable slides: https://bit.ly/49YxtSq

Welcome to Breast Cancer Conversations, the podcast dedicated to empowering those affected by breast cancer. I'm your host, Laura Carfang, a breast cancer survivor and the founder of survivingbreastcancer.org. In this episode, we're diving into a topic that resonates with many in our community: the role of exercise, specifically Pilates, in regaining normalcy after a breast cancer diagnosis.Our guests today are Nina Prol, Bev Breen, and Marie McGuire, who share their insights and personal journeys with Pilates. Nina, a registered nurse with 30 years of experience in adult medical oncology, is also a passionate Pilates instructor. She shares how Pilates, originally developed by Joseph Pilates, is a low-impact exercise that enhances spine flexibility, posture, and core strength, making it ideal for cancer patients.Bev, an executive assistant and breast cancer survivor, recounts her experience with Pilates during her radiation treatment. Despite the challenges of treatment, Pilates provided her with a much-needed mental and physical break. Marie, another member of our community, emphasizes the importance of movement in managing lymphedema and maintaining overall well-being.Throughout the conversation, we discuss the benefits of Pilates for those undergoing cancer treatment, including improved sleep, reduced anxiety, and increased strength. We also touch on the importance of breathwork and mindfulness as tools for stress reduction.As a reminder, while exercise can be a powerful tool in recovery, it's crucial to listen to your healthcare provider's advice and communicate any side effects or concerns. We hope this episode inspires you to explore Pilates or other forms of exercise as part of your recovery journey. Topics Covered: 00:00:03 - Introduction to Breast Cancer Conversations Podcast00:02:12 - Discussing Exercise Post-Cancer Diagnosis00:04:09 - Nina's Introduction and Pilates Journey00:06:12 - Bev's Experience with Breast Cancer and Pilates00:09:42 - Marie's Breast Cancer Story and Pilates Experience00:14:18 - The Benefits of Pilates and Its Accessibility00:24:59 - Discovering Pilates Post-Diagnosis00:30:18 - The Mental Health Benefits of Pilates00:33:09 - Importance of Communication with Healthcare Providers00:35:38 - NCCN Guidelines and Empowering Patients00:37:44 - Questions to Ask Your Doctor+++++++++++++++++++++Attend a free virtual SurvivingBreastCancer.org event:https://www.survivingbreastcancer.org/events+++++++++++++++++++++SurvivingBreastCancer.org's  Mission: To empower those diagnosed with breast cancer and their families from day one and beyond. About SurvivingBreastCancer.org: SurvivingBreastCancer.org, Inc. (SBC) is a federally recognized 501(c)(3) non-profit virtual platform headquartered in Boston with a national and global reach. Through education, community, and resources, SurvivingBreastCancer.org supports women and men going through breast cancer. We provide a sanctuary of strength, compassion, and empowerment, where those diagnosed with cancer unite to share their stories, learn invaluable coping strategies to manage wellness and mental health, and find solace in the unbreakable bond that fuels hope, resilience, and the courage to conquer adversity.+++++++++++++++++++++Follow us on InstagramLaura and Will: https://www.instagram.com/laura_and_will/SurvivingBreastCancer.org: https://www.survivingbreastcancer.org/Support the show

Systemic Therapies for Advanced Prostate Cancer – Short and Long-Term Side Effects CME Available: https://auau.auanet.org/node/39087 At the conclusion of these activities, participants will be able to: 1. Characterize current treatment paradigm for systemic therapies in managing advanced prostate cancer including doublet and triple therapy. 2. Identify short and long-term side effects of ADT and novel hormonal treatments for advanced prostate cancer including cardiovascular, bone health, and metabolic risk. 3. Recognize strategies to monitor and manage side effects of ADT and novel hormonal treatments. 4. Understand adverse effects of newer agents for advanced prostate cancer including PARP inhibitors, immunotherapy, and theranostics. 5. Review management options for adverse effects of newer agents for advanced prostate cancer. This series is supported by independent educational grants from:  Myovant Sciences LTD Pfizer, Inc. REFERENCES: 1. Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials. JAMA 2011;306:2359-2366. 2. NCCN Guidelines for prostate cancer. Version 4.2023. www.nccn.org 3. Lowrance W, Dreicer R, Jarrard DF, et al. Updates to advanced prostate cancer: AUA/SUO guideline (2023). J Urol. 2023;209(6):1082-1090.

Five years, 7 years, or 10 years: How long should follow-up last in melanoma? Dr Sapna Patel and Professor James Larkin discuss the challenges and opportunities. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/989039). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Malignant Melanoma https://emedicine.medscape.com/article/280245-overview NCCN Guidelines. Melanoma: Cutaneous https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1492 Malignant Melanoma Staging https://emedicine.medscape.com/article/2007147-overview A Practical Guide to Understanding Kaplan-Meier Curves https://pubmed.ncbi.nlm.nih.gov/20723767/ SWOG Cancer Research Network https://www.swog.org/ Adjuvant Pembrolizumab Versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma https://pubmed.ncbi.nlm.nih.gov/34764195/ Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma https://pubmed.ncbi.nlm.nih.gov/34818112/ Estimands — A Basic Element for Clinical Trials https://pubmed.ncbi.nlm.nih.gov/34857075/ Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma https://pubmed.ncbi.nlm.nih.gov/36856617/ Definitions of Additional Oncology Drug Endpoints https://www.ncbi.nlm.nih.gov/books/NBK137753/ Adjuvant Nivolumab Versus Ipilimumab in Resected Stage IIIB-C and Stage IV melanoma (CheckMate 238): 4-Year Results From a Multicentre, Double-Blind, Randomised, Controlled, Phase 3 Trial https://pubmed.ncbi.nlm.nih.gov/32961119/ Adjuvant Ipilimumab Versus Placebo After Complete Resection of High-Risk Stage III Melanoma (EORTC 18071): A Randomised, Double-Blind, Phase 3 Trial https://pubmed.ncbi.nlm.nih.gov/25840693/ Adjuvant Pembrolizumab Versus Placebo in Resected Stage III Melanoma (EORTC 1325-MG/KEYNOTE-054): Distant Metastasis-Free Survival Results From a Double-Blind, Randomised, Controlled, Phase 3 Trial https://pubmed.ncbi.nlm.nih.gov/33857412/ Pembrolizumab Versus Placebo as Adjuvant Therapy in Completely Resected Stage IIB or IIC Melanoma (KEYNOTE-716): A Randomised, Double-Blind, Phase 3 Trial https://pubmed.ncbi.nlm.nih.gov/35367007/ The Validity of Progression-Free Survival 2 as a Surrogate Trial End Point for Overall Survival https://pubmed.ncbi.nlm.nih.gov/34985773/ Neoadjuvant Talimogene Laherparepvec Plus Surgery Versus Surgery Alone for Resectable Stage IIIB-IVM1a Melanoma: A Randomized, Open-Label, Phase 2 Trial https://pubmed.ncbi.nlm.nih.gov/34608333/

From MMR/MSI and Neoadjuvant Therapy to "Watch and Wait" and ctDNA, special guests Dr. Al Benson and Dr. Samantha Hendren join the co-hosts for a conversation about the latest NCCN rectal cancer guidelines.     CO-HOSTS Avery Walker, MD, FACS, FASCRS El Paso, TX Avery Walker is dually board-certified in General Surgery and Colorectal Surgery. He earned his medical degree at the University of Illinois in Chicago, his General Surgery residency at Madigan Army Medical Center in Tacoma, Washington, and his Fellowship in Colon and Rectal Surgery at The Ochsner Clinic in New Orleans. A former active-duty officer in the United States Army, Dr. Walker served 13 years as a general and colorectal surgeon with his most recent duty station in El Paso, TX at William Beaumont Army Medical Center. While there he was the Chief of Colon and Rectal surgery as well as the Assistant Program Director for the general surgery residency program. He currently practices colon and rectal surgery at The Hospitals of Providence in El Paso, TX. Dr. Avery Walker is married and has two daughters aged 13 and 9.   Biddy Das, MD, FACS Houston, TX (Twitter @BiddyDas) Dr. Bidhan “Biddy” Das has board certifications for both colon and rectal surgery, and general surgery. His passion for medical education and medical process improvement has resulted in book chapters and publications, and national and regional presentations on those subjects. Highlighting his medical expertise on fecal incontinence, he has been featured on patient education videos and national and international television and radio as a featured expert on these colorectal conditions. Dr Das also has a particular interest in surgeons redefining their careers -- he serves as both a software consultant and private equity consultant in Boston, New York City, and Houston.   Erin King-Mullins, MD, FACS, FASCRS Atlanta, GA (Twitter @eking719) Dr. Erin King-Mullins is a double board-certified general and colorectal surgeon. She graduated summa cum laude from Xavier University of Louisiana. After obtaining her medical degree at Emory University in Atlanta, she completed her internship and residency in general surgery at the Orlando Regional Medical Center in Florida. Her fellowship training in colorectal surgery at Georgia Colon & Rectal Surgical Associates concluded with her joining the practice and serving as Faculty/Research Director for the fellowship program until her transition into private practice with Colorectal Wellness Center. She has a husband with whom she shares an amazing, blended family of 4 daughters. The kids keep them pretty busy, but their favorite times are spent on warm sunny beaches.   Jonathan Abelson, MD, MS Arlington, MA (Twitter @jabelsonmd) Dr. Abelson was born and raised in Scarsdale, New York in the suburbs of New York City.  He has 2 older brothers and both of his parents are dentists.  Dr. Abelson went to college at University Pennsylvania, took 2 years off between college and medical school to work in healthcare consulting.  He then went to medical school at University of Virginia, returned to New York for general surgery residency at Weill Cornell on the upper east side of Manhattan.  Dr. Abelson then did colorectal fellowship at Washington University in St. Louis and am now at Lahey clinic in Burlington, Massachusetts for my first job after training.  He is 2 years into practice and has a wife and two sons. His wife works in wellness consulting and they have a dog named Foster who we adopted in St. Louis.

CME credits: 0.25 Valid until: 27-12-2023 Claim your CME credit at https://reachmd.com/programs/cme/expert-answers-to-common-questions-about-met-exon-14skipping-mutations-in-nsclc/14678/ Non-small cell lung cancer (NSCLC) is a highly heterogeneous disease, and research has evolved its diagnosis and treatment through the discovery of genetic alterations and molecular pathways, personalizing treatment based on tumor mutation(s). The molecular characterization of tumors using techniques such as next-generation sequencing (NGS) has expanded the understanding of actionable molecular alterations, and in tandem has accelerated the development of drugs to inhibit alterations with greater specificity, leading to the development of novel target-selected agents in NSCLC. The NCCN Guidelines strongly advise assessment of at least 8 targets for NSCLC by NGS, including MET exon 14–skipping mutations (METex14). The FDA has approved two MET inhibitors, capmatinib and tepotinib, for patients with METex14 metastatic NSCLC, and there is ongoing research for other targeted agents. Studies have established that treatment with MET-targeted therapies improves outcomes in patients with METex14, as opposed to patients receiving chemotherapy and/or immunotherapy, which generate a modest activity response. AXIS routinely collects and analyzes data gathered from participants in our live activities. These questions provide incredible insight regarding the persistent challenges that clinicians face when trying to optimize treatment and management of patients with cancer to verify where clinical practice gaps exist. That's why this activity will …

CME credits: 0.50 Valid until: 05-01-2024 Claim your CME credit at https://reachmd.com/programs/cme/current-standards-and-future-opportunities-for-adcs-in-advancedmetastatic-triple-negative-breast-cancer/14551/ Antibody-drug conjugates have transformed the treatment of triple-negative breast cancer (TNBC). Tune in to hear about approved ADCs and others in development and find out where they fit into the NCCN Guidelines for TNBC.

In this episode, we explore the role of vascular surgeons in oncologic surgery. We will be discussing the nuances of vascular involvement in oncologic resection, common practices, and future directions of this collaborative surgical culture.   Dr. Adam Beck (@AWBeckMD) is a vascular surgeon and Professor of Surgery at the University of Alabama at Birmingham where he serves as the Director of the Division of Vascular Surgery and Endovascular Therapy, holds the Holt A. McDowell, Jr, MD Endowed Chair in Vascular Surgery and serves as the Director of Quality and Associate Chief Medical Quality Officer for the UAB Cardiovascular Institute. Dr. Beck completed his general surgery residency training and a surgical oncology research fellowship at the University of Texas-Southwestern Medical Center. He trained in vascular surgery at the Dartmouth-Hitchcock Medical Center and then completed a fellowship in advanced endovascular techniques, including branched and fenestrated endografts for aortic aneurysmal disease, at the University Medical Center of Groningen in The Netherlands. You can learn more about Dr. Adam Beck here.   Dr. Xavier Berard (@XavierBerardMD)  is a French vascular surgeon and serves as a Consultant in the Department of Vascular Surgery and Professor of Vascular and Endovascular Surgery in Bordeaux University Hospital in Bordeaux, France. He is board certified from the French College of Vascular and Endovascular Surgeons and from the European Society for Vascular and Endovascular Surgery. He has also completed a PhD in Vascular Biomaterials and has built a library of educational video content. He works closely with Institut Bergonié Bordeaux Cancer Center for sarcomas. You can see educational videos and learn more about Dr. Xavier Berard here   Dr. Sharif Ellozy (@SharifEllozy)  is a vascular surgeon at the New York-Presbyterian/Weill Cornell Medical Center where he serves as Associate Professor of Clinical Surgery in the Division of Vascular and Endovascular Surgery, and Program Director of the Vascular Surgery Fellowship program. He is also one of the founders of Audible Bleeding. He is readily involved in oncologic resection at the Memorial Sloan Kettering Cancer Center and works closely with surgical oncologists on operative cases that have vessel involvement.   Authors/Interviewers: Dr. Sree Kanna, MD - McGill, Montreal (@VulnerableAorta) Dr. Nakia Sarad, DO, MS - New York-Presbyterian/Queens - Weill Cornell, New York (@NakSaradDO)   Editors: Morgan Gold, MD,CM candidate - McGill, Montreal (@MorganSGold) Ezra Schwartz, MD,CM, MS, MMSc-Med Ed candidate - Harvard, Boston (@EzraSchwartz10)   Helpful Resources:   To learn more about sarcoma resections, check out the Schwarzbach papers on lower extremity sarcomas and retroperitoneal sarcomas   Click here to learn more about the NCCN Guidelines on Resectability of Pancreatic Cancers   Click here to learn more about IVC Reconstruction Techniques in Oncologic Surgery   Video of IVC Leiomyosarcoma Reconstructions here (courtesy of Dr. Berard)   Click here to learn more about the Renal Cell Carcinoma Mayo Staging System Click here to find the original article on the Shamblin Classification for Carotid Body Tumors   Check out this review paper on Oncovascular Surgery    Check out this paper on spiral endografts here Video of spiral saphenous vein graft technique here (courtesy of Dr. Berard)   What other topics would you like to hear about? Let us know more about you and what you think of our podcast through our Listener Survey or email us at AudibleBleeding@vascularsociety.org. Follow us on Twitter @audiblebleeding   Learn more about us at https://www.audiblebleeding.com/about-1/ and #jointheconversation.  

NCCN Policy & Advocacy Priorities Supporting high quality cancer care through the NCCN Guidelines is a strategic pillar for the NCCN. Alyssa Schatz is the Senior Director of Policy & Advocacy at the National Comprehensive Cancer Network. She shares the current strategic priorities for her team in this week's episode.

Lung cancer is one of the most commonly diagnosed type of cancer and so it is fitting that we start the first of our disease-specific oncology series with this diagnosis. This week, we continue our discussion on metastatic non-small cell lung cancer, focusing on NSCLC with driver mutations. * The approach to treatment of a patient with widespread metastatic NSCLC (mNSCLC) is very different than a patient without distant disease, which highlights why we do what we do:- Important to complete staging (discussed in prior episodes) to determine the extent of disease- Important to check molecular testing (looking for mutations in the cancer cells) and IHC for tumor proportion score (TPS) helps determine treatment options - If your molecular testing is identified in a driver mutation gene, there are targeted options for this! *Driver mutations are predictive of response to an oral therapy and a LACK of response to immune therapy (particularly in EGFR and ALK mutated patients) * EGFR Mutation:- Pay attention to the types of mutation in EGFR (not all are the same):-- Exon 19 deletion -- Exon 19 L858R-- Exon 21 T790M-- Exon 20 Insertion (Osimertinib [see below] cannot be used for this mutation)- Osimertinib is first-line standard of care for patients with EGFR-- Used to be a second-line agent. Many patients with EGFR mutations receiving earlier generation TKIs would develop resistance and when these tumors were sequenced, they would have Exon 21 T790M mutations. Osimertinib was effective even with this mutation and had superior overall survival data compared to chemotherapy (AURA3 Trial)--Now it is used in first-line setting for patients with EGFR mutation based on the FLAURA trial --- In this study, patients received osimertinib as first line vs. older generation EGFR-targeting TKIs (erlotinib or gefitib) and Osimertinib had better outcomes: ---- Showed that the median OS was 38.6 months with Osi vs. 31.8 months; also improved brain penetration! ---- Also effective in patients with metastatic disease to the brain: ----- Only 6% of patients had CNS progression with Osi vs. 15% with others- What if a patient is on Osi and later develops new brain mets?-- If there is progression within just the brain (and good control in other sites of the body) you can refer patient to Radiation Oncology for SRS-- Remember, based on discussion with Dr. Osmundson in our RadOnc lectures (Episode 028), it is important to HOLD Osimertinib if patient is going to get radiation to minimize the side effects- What is patient had progression of disease in several sites throughout the body?-- Management is less straightforward. -- In many of these cases, you can consider:--- Consolidative radiation - If small amounts of disease--- Changing therapy - If there has been widespread progression; likely would change to chemotherapy (without IO, since lower predictive response to IO with EGFR mutation)---- No clear guidelines if you should continue the TKI---- Remember that IO + TKIs can cause increased risk of side effects, such as pneumonitis and hepatitis. DO NOT DO THIS!* ALK Mutation:- There are many options for ALK mutations-- The first generation drug is crizotinib--- Lots of side effects —> “It is crazy to start with crizotinib”--- Studies for later generation TKIs were compared to crizotinib -- Many people today will use third generation ALK-inhibitor alectinib (Important trials: ALEX Trial and J-ALEX Trial)--- With alectinib, PFS 34.8 months, RR 83%, less CNS progression (12% vs 45%)--- 5 year OS rate 62.5%- What to do with disease progression while on ALK inhibitor?-- In ALK, you can actually switch to another ALK inhibitor and many will respond well--- Of course, with each change, you may expect not as great of a response * Lots of other mutations!- TFOC recommends just looking these up!-- Link to NCCN Guidelines on NSCLC; Page 41 has full list!- Another way to think about this, when do we NOT do TKIs as first line: -- KRAS G12C-- EGFR Exon 20 Insertion-- HER2- How do you counsel a patient when considering/starting a TKI? -- Patients with highest chance of having a targeted mutation are younger non-smokers with adenocarcinoma-- Set expectations: great outcomes overall, but still not a cure. -- Remembering the drugs: All TKIs usually end in “-nib” -- In general, the way we recommend remembering this: “Fatigue, GI, Derm (skin/nail changes)”; rarely pneumonitis References:* AURA3 Trial - https://www.nejm.org/doi/full/10.1056/NEJMoa1612674Established osimertinib was better than chemo for patients with EGFR mutation and acquired Exon 21 T790M resistance mutation* FLAURA Trial - https://www.nejm.org/doi/full/10.1056/nejmoa1713137 Established osimertinib as first-line agent for patients with EGFR mutation * ALEX Trial - https://www.nejm.org/doi/full/10.1056/nejmoa1704795Helped establish alectinib as superior for ALK mutations compared to crizotinib * J-ALEX Trial - https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)30565-2/fulltextHelped establish alectinib as superior for ALK mutations compared to crizotinib * NCCN Guidelines on NSCLC - https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1450 Please visit our website (TheFellowOnCall.com) for more information Twitter: @TheFellowOnCallInstagram: @TheFellowOnCallListen in on: Apple Podcast, Spotify, and Google PodcastLove what you hear? Tell a friend and leave a review on our podcast streaming platforms!

Myriad  Live episodes are recordings of an open-forum webinar hosted by Dr. Thomas Slavin. The opinions and views expressed in this recording do not necessarily represent those of Myriad Genetics or its affiliates. To participate in a future recording, visit https://myriad.com/live/ for a list of dates, times, and subjects.References for this episode:Genome web article: https://www.genomeweb.com/sequencing/early-cancer-detection-li-fraumeni-syndrome-patients-enabled-liquid-biopsy-testAbstract: https://acmg.planion.com/Web.User/AbstractDet?ACCOUNT=ACMG&CONF=AM22&ssoOverride=OFF&ABSID=12124CHARM consortium https://charmconsortium.ca/NCCN Guidelines: https://www.nccn.org/professionals/physician_gls/pdf/genetics_bop.pdfTumor-Based Genetic Testing and Familial Cancer Risk https://pubmed.ncbi.nlm.nih.gov/31570381https://liftupstudy.org/https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.1514

In this episode, we will be learning about an occupational therapy practitioner in oncology. Vanessa Monique Yanez, MSOT, OTR/L is an occupational therapist with a specialization in oncology. She is a cancer survivor and an advocate for rehabilitative services across the continuum of cancer care, from prevention to survivorship. She holds a faculty position at the University of St. Augustine and runs a private practice in San Antonio, TX. Vanessa is a frequent presenter at state and national conferences and is currently pursuing a Ph.D. from Texas Woman's University. She strongly believes that occupational therapy coalesces compassion, research, and a client-centered approach in a unique way that can help cancer survivors not only function but fully participate in a life they deserve. Her clinical and research interests include hematological cancers, stem cell transplants, psychosocial supportive care, sexual functioning, and theory-driven practice in cancer care. Show Key Points:· Vanessa gives us a glimpse of her background and interests· Vanessa describes her Uncommon OT work, the setting, and population she serves· Vanessa describes what drew her to this type of work and her path there· Vanessa describes typical goals sessions · Vanessa dispels some myths about the profession· Vanessa provides other OTPs valuable advice· Vanessa provides her contact information RESOURCES:a) Assessment tools at FACIT.org https://www.facit.org/facit-measures-searchable-libraryb) Functional Assessment of Chronic Illness Therapy - Fatigue Scale (FACIT-F) https://www.facit.org/measures/FACIT-Fatiguec) Functional Assessment of Cancer Therapy - Cognitive Function (FACT-Cog): https://www.facit.org/measures/FACT-Cogd) Psychosocial article by Sleight & Duker (2016): https://research.aota.org/ajot/article-abstract/70/4/7004360030p1/6182/Toward-a-Broader-Role-for-Occupational-Therapy-in?redirectedFrom=fulltexte) Systematic Review of OT and Adult Cancer Rehab (Part I) by Hunter et al. (2017): https://research.aota.org/ajot/article-abstract/71/2/7102100030p1/6304/Systematic-Review-of-Occupational-Therapy-and?redirectedFrom=fulltextf) Systematic Review of OT and Adult Cancer Rehab (Part II) by Hunter et al. (2017): https://research.aota.org/ajot/article-abstract/71/2/7102100040p1/6287/Systematic-Review-of-Occupational-Therapy-and?redirectedFrom=fulltextg) Occupational Therapy Group Intervention in Oncology: A Scoping Review by Udovicich (2020)https://research.aota.org/ajot/article-abstract/74/4/7404205010p1/8439/Occupational-Therapy-Group-Interventions-in?redirectedFrom=fulltexth) NCCN Guidelines: https://www.nccn.org As always, I welcome any feedback & ideas from all of you or if you are interested in being a guest on future episodes, please do not hesitate to contact Patricia Motus at transitionsot@gmail.com or DM via Instagram @transitionsotTHANK YOU for LISTENING, FOLLOWING, DOWNLOADING, RATING, REVIEWING & SHARING “The Uncommon OT Series” Podcast with all your OTP friends and colleagues! Full Episodes and Q & A only available at: https://www.wholistic-transitions.com/the-uncommon-ot-series Sign Up NOW for the Transitions OT Email List to Receive the FREE Updated List of Uncommon OT Practice Settingshttps://www.wholistic-transitions.com/transitionsot Happy Listening Everyone! Big OT Love!All views are mine and guests own.Be a Patron to support The Uncommon OT Series Podcast project via Patreon.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Thomas Kipps, MD, PhD What do the NCCN guidelines recommend for the management of patients with chronic lymphocytic leukemia, or CLL, and mantle cell lymphoma, or MCL? Dr. Charles Turck is joined by Dr. Thomas Kipps to talk about prognostic risk indicators, current therapeutic agents, and adverse events for patients with CLL and MCL.

Welcome to Episode 010 of the Beyond the Diagnosis Podcast. In this episode Kathy welcomes back Deanna Fournier, Executive Director of the Histiocytosis Association for a conversation about what the Association has accomplished this year and what is planned for 2022. If you're curious about the exciting things that Association has been up to this year and the plans we have for the new year, then you don't want to miss this episode! Let us know what you think! Leave us a review, drop us a comment or share an idea for a future podcast with us at podcast@histio.org. Take a screenshot and tag us @histiocytosis_association on Instagram. We'd love to hear your feedback! Resources mentioned in the podcast: https://www.pcori.org/ Educational Webinars: https://histio.org/resource-overview/education-connection/ Information on NCCN Guidelines: https://histio.org/histiocytic-disorders/ Music: “Heroes” by Noah Smith

Doctors' appointments can be overwhelming, especially after a cancer diagnosis. There are so many questions to ask even before walking into the office, and then once a treatment plan is presented there are even more questions.On the latest episode of The Cancer Pod, Tina and Leah review some of the questions to bring up at an oncology appointment and offer some tips to help patients, both newly diagnosed and seasoned veterans, about what to bring to appointments. They even delve into the topic of what to do if you don't like your doctor or what happens if your doctor leaves you.The Trapper Keeper is Back!NCCN Guidelines for PatientsCancer.net - Questions to Ask Your Health TeamAmerican Cancer Society - Questions to Ask Your DoctorSupport the show (https://www.buymeacoffee.com/thecancerpod)

The National Comprehensive Cancer Network's 2021 Virtual Congress on Hematologic Malignancies took place from October 14 to October 16. The meeting focused on updates to the NCCN Guidelines; new, emerging, and novel therapeutic agents; advances in cancer care; and the practical management of patients with hematologic malignancies. This week, we hear from three presenters who participated in the conference.To listen to more podcasts from ASCO, visit asco.org/podcasts.

Presenter:Gail J. Roboz MDProfessor of MedicineDirector, Clinical and Translational Leukemia ProgramWeill Medical College of Cornell UniversityNew York-Presbyterian HospitalNew York, New York, United StatesThis brief program will begin with a review of NCCN Guidelines® Recommendations for the treatment of AML in individuals 60 years of age or older. Next, the results of the BRIGHT AML 1003 trial comparing glasdegib + LDAC to LDAC alone, the VIALE-A trial comparing venetoclax + azacitidine vs azacitidine alone, and a comparison of CPX-351 vs standard of care cytarabine + daunorubicin (7 + 3 regimen) for induction and consolidation, will be reviewed. The faculty will discuss FLT3 and IDH inhibitor approvals for AML, IDK differentiation syndrome, and measuring MRD in AML. Finally, results of a trial examining oral azacitidine and a meta-analysis of 5 trials examining gemtuzumab ozogamicin will be reviewed.https://www.clinical-care.org/resource-center-details/using-available-evidence-and-guidelines-for-managing-an-evolving-aml-treatment-paradigmFollow along with the slideset located here:https://bit.ly/3lJNHYC  

Rick Greene, MD, and Elisa Port, MD, discuss surgeon adherence to NCCN guidelines and patterns of testing in newly diagnosed breast cancer patients. Dr. Port is author of, “Adherence to NCCN Guidelines for Genetic Testing in Breast Cancer Patients: Who Are We Missing?” Dr. Port is Chief of Breast Surgery and Director of the Dubin Breast Center, Mount Sinai Hospital, and  Professor of Surgery, Icahn School of Medicine at Mount Sinai, New York, New York.

This week, CancerNetwork review an article published in the July issue of the journal ONCOLOGY titled, “Level of Scientific Evidence Underlying the National Comprehensive Cancer Network Clinical Practice Guidelines for Hematologic Malignancies.” CancerNetwork spoke with Thejaswi Poonacha, MD, MBA, a staff physician and hospitalist in the department of internal medicine at the University of Minnesota Medical Center, regarding the research from him and his colleagues. The conversation focused on the scientific evidence behind the NCCN guidelines for hematologic malignancies, how each category corresponds with different levels of evidence, and the main findings from this study. Poonacha shared exactly what this means, and why this research was so significant for this group of authors. Don't forget to subscribe to the "Oncology Peer Review On-The-Go" podcast on Apple Podcasts, Spotify or anywhere podcasts are available.

CME credits: 0.50 Valid until: 13-06-2022 Claim your CME credit at https://reachmd.com/programs/cme/improving-quality-care-patients-harboring-alk-nsclc/12631/ The discovery of predictive biomarkers, such as sensitizing epidermal growth factor receptor (EGFR) mutations, anaplastic lymphoma kinase (ALK) rearrangements, ROS1 rearrangements, and BRAF V600E mutations has led to an improvement in overall survival and progression-free survival in non–small cell lung cancer (NSCLC) by identifying subgroups of patients who benefit from targeted treatment. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines®) note, “For patients with recurrent and metastatic disease, the NCCN Guidelines recommend that histologic subtype should be determined before therapy so that the best treatment can be selected. In addition, biomarker testing for genetic alterations (ie, oncogenic driver events) is recommended in patients with NSCLC, because targeted therapy has been shown to decrease tumor burden, decrease symptoms, and dramatically improve the quality of life for patients with specific genetic alterations. The number of available targeted agents is increasing.” (Ettinger et al, 2020.) Approximately 5% of patients with NSCLC have ALK gene rearrangements. One of the most noteworthy areas of progress is the development of effective ALK-targeting therapies to treat NSCLC, including crizotinib, ceritinib, alectinib, brigatinib, and lorlatinib. Because of the fast pace of developments in this area, it may be difficult for clinicians to remain up-to-date on ...

CME credits: 0.50 Valid until: 13-06-2022 Claim your CME credit at https://reachmd.com/programs/cme/improving-quality-care-patients-harboring-alk-nsclc/12631/ The discovery of predictive biomarkers, such as sensitizing epidermal growth factor receptor (EGFR) mutations, anaplastic lymphoma kinase (ALK) rearrangements, ROS1 rearrangements, and BRAF V600E mutations has led to an improvement in overall survival and progression-free survival in non–small cell lung cancer (NSCLC) by identifying subgroups of patients who benefit from targeted treatment. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines®) note, “For patients with recurrent and metastatic disease, the NCCN Guidelines recommend that histologic subtype should be determined before therapy so that the best treatment can be selected. In addition, biomarker testing for genetic alterations (ie, oncogenic driver events) is recommended in patients with NSCLC, because targeted therapy has been shown to decrease tumor burden, decrease symptoms, and dramatically improve the quality of life for patients with specific genetic alterations. The number of available targeted agents is increasing.” (Ettinger et al, 2020.) Approximately 5% of patients with NSCLC have ALK gene rearrangements. One of the most noteworthy areas of progress is the development of effective ALK-targeting therapies to treat NSCLC, including crizotinib, ceritinib, alectinib, brigatinib, and lorlatinib. Because of the fast pace of developments in this area, it may be difficult for clinicians to remain up-to-date on ...

Dr. Jose Silva talks with Urologist Dr. Aditya Bagrodia from UT Southwestern Medical Center about the medical and surgical management of testicular cancer. --- EARN CME Reflect on how this Podcast applies to your day-to-day and earn AMA PRA Category 1 CMEs: https://earnc.me/Em4or1 --- SHOW NOTES In this episode of BackTable Urology, urologic oncologist Dr. Aditya Bagrodia joins our host Dr. Jose Silva to discuss the diagnosis, treatment, and long-term management of testicular cancer. The episode begins with an algorithm for initial work up of a testicular mass – scrotal ultrasound and tumor markers – and reviews the pre-orchiectomy timing of additional imaging and when more advanced imaging modalities like MRI or contrast-enhanced CT might be clinically useful. Dr. Bagrodia then walks through his surgical technique, highlighting practical tips to avoid common frustrations and complications. The pair also discuss operative technique and optimal timing for placement of testicular prostheses, as well as the role for partial orchiectomy in patients prioritizing fertility preservation and androgen production. Dr. Bagrodia discusses indications for adjuvant chemotherapy and radiation, with a focus on avoiding over-treatment in these young patients and opting for observation when appropriate. He reviews surveillance protocols based on pathological stage, then walks through the management of recurrent and metastatic disease with an emphasis on the importance of multidisciplinary care. The episode ends with an overview of Dr. Bagrodia's current research, microRNAs. He reviews the sensitivity and specificity of these unique microRNAs in testicular cancer, explaining their potential to truly individualize care by correctly diagnosing equivocal tumors and identifying residual or recurrent disease. --- RESOURCES AUA Guidelines: https://www.auanet.org/guidelines/guidelines/testicular-cancer-guideline EAU Guidelines: https://uroweb.org/guideline/testicular-cancer/ NCCN Guidelines: https://www.nccn.org/professionals/physician_gls/pdf/testicular.pdf

During the National Comprehensive Cancer Network (NCCN) 2021 Annual Conference, the Multiple Myeloma Hub spoke to Natalie S. Callander, University of Wisconsin-Madison, Madison, US and Shaji K. Kumar, Mayo Clinic, Rochester, US. We asked, What are the key additions to the new NCCN guidelines for multiple myeloma?Callander and Kumar discuss the inclusion of new diagnostic tools, such as MRD testing, risk-stratification for MM and it's precursor stages, and changes to treatment regimens for newly diagnosed and relapsed MM. Callander also describes an important update for the recommendation of the combination of daratumumab, cyclophosphamide, bortezomib, and dexamethasone for the treatment of amyloidosis, providing supporting data from the phase III ANDROMEDA trial. They finish by discussing risk stratification and treatment intervention updates for smoldering MM. Hosted on Acast. See acast.com/privacy for more information.

This week, we'll be discussing a recent presentation that parsed out differences in disease seen in younger vs older women with breast cancer. We'll also hear about an update to the NCCN Guidelines for triple-negative breast cancer.To listen to more podcasts from ASCO, visit asco.org/podcasts.

On this episode of the Cancer Dietitian Podcast we're discussing diagnosis and treatment of colon cancer with Joyce Fenstermaker, a GI Oncology Nurse Navigator at Wake Forest Baptist Health Comprehensive Cancer Center, about the colon cancer screening and treatment process and coping with the anxiety that comes with a diagnosis. We also chat with cancer survivor and Board-Certified Medical Oncologist at Novant Health Oncology Specialists, Dr. Eugene Paschold about his personal cancer experience as well as his advice for patients from a doctor and patient perspective. What we discuss: How the process works When it's time to make treatment decisions Why you should be asking for a second opinion How to cope with the anxiety of a diagnosis and treatment Where to go for help How caregivers, friends and family can help someone facing a diagnosis of colon cancer Links mentioned: NCCN Guidelines for Colon Cancer Patients Wake Forest Baptist Comprehensive Cancer Center Novant Health Oncology Specialists Cancer Services, Inc. Cancer Dietitian Colon Cancer Coalition Get Your Rear in Gear 2020 Race Race Facebook Event Page

Currently SVP of Oncology and Specialty Market Programs at Aventria Health Group.  Formerly was  CCO at Favrille, VP Strategic Marketing at Schering AG and Head of Oncology Marketing at Genentech; was instrumental in the commercialization of Taxotere, Fludara, Herceptin, and Rituxan 00:00 New Oncology Breakthroughs. 02:35 Extending survival time to stabilizing curves that could extend to future cures. 03:50 The average cost of a new Oncology product is more than $100,000 for annual cost of treatment. 04:15 “The question is how, as a Health System, we're going to be able to manage that.” 04:30 What Payers are doing to afford these new Oncology Breakthroughs. 04:50 Creating Pathways and Incentivizing Providers to use these Pathways. 05:20 The difference between a Pharmacy Benefit and a Medical Benefit. 05:50 “Buy and Bill.” 06:30 The potential for Providers to make a significant portion of their income from purchasing more expensive products. 07:00 Medicare's adopted average selling price & demonstration project for Buy and Bill. 07:50 How Bundled Payments is affecting the cost of Oncology. 09:00 The Oncology Care Model and shifting to an Episodic Care Model. 09:50 The Evidence-Based approach to treating patients. 10:15 NCCN Guidelines. 11:00 “As long as the Pathways reflect the Gold Standard.” 11:50 Payers are trying to get more consistent care, rather than trying to limit the cost of care. 12:15 Laws requiring Payers to cover Oncology treatment. 14:00 The importance for Manufacturers to communicate and demonstrate the value of their medication. 15:00 Creating a Step Approach. 16:20 Change in the future allowing Medicare negotiate prices with manufacturers. 17:50 David's advice for Pharmaceutical manufacturers. 18:15 Value-Based Contracting. 18:40 Risk-Sharing Program. 19:20 Paying by the Pill vs. Paying by the Value Medication Delivers. 19:40 A more Value-Based Reimbursement system. 20:00 You can find out more at AventriaHealth.com.

SURVIVOR SPOTLIGHT MICHELLE GOODWIN 2x YA Survivor, Non-Hodgkin Lymphoma Art Director/Photographer Creator, Malignant Humor REBECCA H JOHNSON, MD Medical Director Adolescent and Young Adult Program Seattle Children's Hospital PETER F. COCCIA, MD Section Chief Division of Hematology/Oncology University of Nebraska Medical Center

SURVIVOR SPOTLIGHT MICHELLE GOODWIN 2x YA Survivor, Non-Hodgkin Lymphoma Art Director/Photographer Creator, Malignant Humor REBECCA H JOHNSON, MD Medical Director Adolescent and Young Adult Program Seattle Children's Hospital PETER F. COCCIA, MD Section Chief Division of Hematology/Oncology University of Nebraska Medical Center See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.